Sansure Biotech Inc. (688289.SS)
CNY 19.81
(-0.4%)
CNY 19.81
(-0.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 574.93 Million CNY | -95.49% |
| 2022 | 2.43 Billion CNY | 1.13% |
| 2021 | 2.67 Billion CNY | -16.41% |
| 2020 | 3.09 Billion CNY | 4412.28% |
| 2019 | 68.62 Million CNY | 79.57% |
| 2018 | 32.46 Million CNY | -4.89% |
| 2017 | 39.68 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 88.69 Million CNY | 4.01% |
| 2024 Q2 | 60.51 Million CNY | 29.26% |
| 2024 Q3 | 37.38 Million CNY | -70.4% |
| 2023 Q2 | 1.63 Million CNY | -96.12% |
| 2023 FY | - CNY | -95.49% |
| 2023 Q1 | 42.23 Million CNY | -94.13% |
| 2023 Q3 | 233.68 Million CNY | 14149.55% |
| 2023 Q4 | 57.54 Million CNY | -75.38% |
| 2022 Q4 | 719.64 Million CNY | 31.43% |
| 2022 Q2 | 524.92 Million CNY | -29.95% |
| 2022 Q1 | 749.38 Million CNY | 50.0% |
| 2022 Q3 | 547.56 Million CNY | 4.31% |
| 2022 FY | - CNY | 1.13% |
| 2021 Q1 | 723.31 Million CNY | 3.88% |
| 2021 Q2 | 583.22 Million CNY | -19.37% |
| 2021 FY | - CNY | -16.41% |
| 2021 Q4 | 499.58 Million CNY | -32.58% |
| 2021 Q3 | 741.04 Million CNY | 27.06% |
| 2020 FY | - CNY | 4412.28% |
| 2020 Q4 | 696.28 Million CNY | -24.21% |
| 2020 Q1 | 239.16 Million CNY | 845.52% |
| 2020 Q2 | 1.24 Billion CNY | 419.77% |
| 2020 Q3 | 918.71 Million CNY | -26.09% |
| 2019 FY | - CNY | 79.57% |
| 2019 Q3 | 10.62 Million CNY | -36.66% |
| 2019 Q2 | 16.77 Million CNY | 176.35% |
| 2019 Q1 | 6.06 Million CNY | 0.0% |
| 2019 Q4 | 25.29 Million CNY | 138.1% |
| 2018 FY | - CNY | -4.89% |
| 2017 FY | - CNY | 0.0% |